低强度冲击波疗法和每日使用塔达拉菲尔的联合治疗对严重勃起功能障碍的影响:双盲,随机化,假控制的临床试验
Dimitrios Kalyvianakis1,2, Ioannis Mykoniatis1, Nikolaos Pyrgidis2,3
1Department of Urology, Aristotle University of Thessaloniki, Thessaloniki 54635, Greece.
The journal of sexual medicine
|April 11, 2024
概括
低强度冲击波疗法 (LiST) 与每日使用塔达拉菲尔相结合,可显著改善严重血管性勃起障碍男性的勃起功能. 这种组合疗法为具有挑战性的病例提供了一个有希望的非侵入性选择,显示出比单独使用塔达拉菲尔的持续益处.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 安德罗学与人类学
- 再生医学是一种再生医学.
背景情况:
- 严重的勃起功能障碍 (ED) 对非侵入性治疗选择提出了重大挑战.
- 特别是血管性ED,需要有效的治疗策略.
研究的目的:
- 评估结合低强度冲击波疗法 (LiST) 与每日使用塔达拉菲尔在严重血管性ED患者中的疗效.
- 在双盲随机试验中,将联合治疗与tadalafil单疗法进行比较.
主要方法:
- 48名患有严重血管性ED的男性接受了12次LiST治疗,每周3次,每天服用tadalafil或假药治疗,每天服用tadalafil,持续4周.
- 在治疗后1个月和3个月,使用国际勃起功能指数-勃起功能域 (IIEF-EF) 和性接触概况 (SEP) 日记评估勃起功能.
主要成果:
- 与虚假组相比,接受LiST加tadalafil的患者在1个月 (12.1 vs 10.2) 和3个月 (12.9 vs 10.8) 的IIEF-EF得分显著更高.
- 在3个月后,在组合治疗组中更频繁地观察到临床上有意义的改善 (IIEF-EF≥7分).
- 在这两组中都没有报告与治疗相关的不良事件.
结论:
- 使用LiST和每日使用tadalafil的联合治疗可为严重血管性ED患者提供短期改善勃起功能.
- 这种方法可能是一个可行的非侵入性治疗选择,对于患者严重的ED不响应单独的tadalafil.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
150
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
150
Electroconvulsive Therapy
39
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
39
Disorders of the Male Reproductive System
402
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
402
Male Sexual Response: Erection & Ejaculation
2.2K
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
2.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
160
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
160

